Origin licensing and p53 status regulate Cdk2 activity during G1 by Nevis, Kathleen R. et al.
Origin licensing and p53 status regulate Cdk2 activity during G1
Kathleen R. Nevis1, Marila Cordeiro-Stone1,2,3, and Jeanette Gowen Cook2,4,*
1Department of Pathology and Laboratory Medicine; University of North Carolina; Chapel Hill, NC
USA
2Lineberger Comprehensive Cancer Center; University of North Carolina; Chapel Hill, NC USA
3Center for Environmental Health and Susceptibility; University of North Carolina; Chapel Hill, NC
USA
4Department of Biochemistry and Biophysics; University of North Carolina; Chapel Hill, NC USA
Abstract
Origins of DNA replication are licensed through the assembly of a chromatin-bound prereplication
complex. Multiple regulatory mechanisms block new prereplication complex assembly after the
G1/S transition to prevent rereplication. The strict inhibition of licensing after the G1/S transition
means that all origins used in S phase must have been licensed in the preceding G1. Nevertheless
mechanisms that coordinate S phase entry with the completion of origin licensing are still poorly
understood. We demonstrate that depletion of either of two essential licensing factors, Cdc6 or Cdt1,
in normal human fibroblasts induces a G1 arrest accompanied by inhibition of cyclin E/Cdk2 activity
and hypophosphorylation of Rb. The Cdk2 inhibition is attributed to a reduction in the essential
activating phosphorylation of T160 and an associated delay in Cdk2 nuclear accumulation. In
contrast, licensing inhibition in the HeLa or U2OS cancer cell lines failed to regulate Cdk2 or Rb
phosphorylation, and these cells died by apoptosis. Co-depletion of Cdc6 and p53 in normal cells
restored Cdk2 activation and Rb phosphorylation, permitting them to enter S phase with a reduced
rate of replication and also to accumulate markers of DNA damage. These results demonstrate
dependence on origin licensing for multiple events required for G1 progression, and suggest a
mechanism to prevent premature S phase entry that functions in normal cells but not in p53-deficient
cells.
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Introduction
DNA replication in human cells initiates at thousands of origins to ensure that each
chromosome is completely replicated each cell cycle. The combined action of the Origin
Recognition Complex (ORC) with the Cdc6 and Cdt1 proteins results in the recruitment and
chromatin loading of a poised, but inactive DNA helicase, the Minichromosome Maintenance
Complex (MCM). MCM loading at an origin completes the assembly of a prereplication
complex (preRC) and marks that origin as “licensed” for DNA replication.1–5
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From the onset of S phase until late mitosis, multiple overlapping mechanisms prevent new
origin licensing by inducing the degradation of preRC components, blocking their interaction
with one another, or inhibiting their association with chromatin.6–9 In this manner, cells are
protected from the consequences of unscheduled origin licensing and the inappropriate
rereplication that could then arise. Once the G1/S phase boundary has been crossed, cells do
not have the opportunity to license additional origins. Therefore if too few origins were licensed
in the preceding G1, cells could become trapped in S phase with partially replicated
chromosomes. Ultimately, insufficient origin licensing could lead to chromosome
fragmentation and cell death, or rearrangements and genome instability, making it crucial that
enough origins are licensed in G1 prior to S phase entry.
Given the potential danger of entering S phase before licensing is complete, it would be
advantageous for cells to delay entry into S phase until at least a minimum number of origins
have been licensed. Indirect evidence for the existence of such an “origin licensing checkpoint”
was first derived from the observation that licensing inhibition in normal cells induces an
apparent G1 arrest, but tumor-derived cells activate a robust apoptotic response.10–12 These
findings suggested that genetic alterations in cancer cells perturb a relationship between origin
licensing and S phase entry that protects normal cells from attempting an S phase that is doomed
to fail. However, the mechanisms that prevent S phase entry in normal cells with insufficiently
licensed origins have not been fully elucidated.
In the present study, we provide evidence for a link in normal cells between origin licensing
in G1 and Cdk2 activation by phosphorylation on T160. We demonstrate that a G1 arrest
induced by insufficient origin licensing is accompanied by loss of Cdk2 activation and Rb
hyperphosphorylation. In normal cells, the p53 tumor suppressor is required for the dependence
of Rb and Cdk2 phosphorylation on origin licensing. In the absence of p53, licensing-deficient
cells enter S phase and subsequently acquire markers of DNA damage. Moreover two cancer
cell lines with documented deficiencies in p53 regulation fail to link Cdk activation with origin
licensing and die by apoptosis with the same DNA damage markers as normal cells depleted
of p53. Together these findings establish a relationship between origin licensing and Cdk2
activation that protects normal cells, but not cancer cells, from inappropriate S phase entry.
Results
Cdc6 depletion induces apoptosis in cancer cells, but not in normal human fibroblasts
To investigate the relationship between origin licensing and S phase entry, we examined the
effects of suppressing origin licensing in two cancer cell lines, HeLa and U2OS, and in
immortalized diploid fibroblasts NHF1-hTert (hereafter abbreviated as NHF1).15 Transfection
with siRNA targeting the essential replication licensing factor, Cdc6, resulted in substantial
depletion of Cdc6 protein to levels nearly undetectable by immunoblotting (Fig. 1A). In the
HeLa and U2OS cells, we observed morphological changes associated with cytotoxicity and
a substantial number of floating cells after transfection with cdc6 siRNA but not a control
siRNA targeting GFP. In contrast, we observed no such effects of the cdc6 siRNA on the NHF1
cells (data not shown). Flow cytometric analysis of DNA content indicated that cdc6 siRNA,
but not control siRNA, induced a substantial increase in the number of HeLa and U2OS cells
with sub-G1 DNA content, a marker of apoptosis (Fig. 1B). Cdc6-depleted HeLa and U2OS
cells also displayed high levels of cleaved caspase-3, but Cdc6-depleted NHF1 cells did not
(Fig. 1C).
We noted that the population of cells with an S phase DNA content was not markedly reduced
in Cdc6-depleted HeLa or U2OS cells compared to control cells whereas the Cdc6-depleted
NHF1 cells accumulated a G1 DNA content (Fig. 1B). To determine if indeed the Cdc6-
depleted NHF1 cells had arrested in G1, we analyzed BrdU-labeled cells by flow cytometry
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72 h after transfection with control siRNA (targeting GFP) or cdc6 siRNA. Compared to control
cells, Cdc6 depletion resulted in a decreased number of S phase cells and a concomitant increase
in the number of G1 cells (Fig. 1D). (The small population of cells incorporating BrdU after
cdc6 siRNA transfection presumably includes cells with residual Cdc6 protein, and even these
incorporated lower levels of BrdU than control cells.) To confirm that the depletion of Cdc6
was sufficient to inhibit replication licensing in these cells, we monitored the association of
the MCM subunit, Mcm2, with chromatin by an established chromatin fractionation protocol.
13,16 As expected, Cdc6 depletion resulted in a reduction of chromatin-bound Mcm2,
illustrating a deficiency in origin licensing (Fig. 1E, top row, compare lanes 3 and 4).
If the Cdc6-depleted normal cells were indeed delaying the G1/S transition, as suggested by
the flow cytometry data, these observations would be consistent with a checkpoint-like
relationship between origin licensing and S phase entry. Since Cdc6 is an essential DNA
replication factor however, we considered assays of BrdU incorporation to be insufficient to
accurately determine the cell cycle position of Cdc6-depleted cells. To address this question,
we examined molecular markers of the G1/S transition. If Cdc6-depleted cells were in G1, we
would expect the retinoblastoma protein, Rb, to be hypophosphorylated and Cdk activity,
specifically cyclin D and cyclin E-stimulated Cdks, to remain low. On the other hand, if Cdc6-
depleted cells entered S phase, then we would expect high Cdk activity and Rb
hyperphosphorylation. We examined the phosphorylation state of Rb by SDS-PAGE mobility
and with a phosphospecific antibody. Cdc6 depletion induced an increase in the gel mobility
of total Rb protein indicating general hypophosphorylation (Fig. 2A, compare lanes 1 and 2)
and a decrease in specific phosphorylation of Rb at serines 807 and 811 (Fig. 2A, compare
lanes 3 and 4) in comparison to control cells. Phosphorylation of Rb is carried out by both
cyclin D-Cdk4/6 and cyclin E/Cdk2,17–20 therefore we examined whether loss of cyclin D or
cyclin E protein could account for the lack of Rb phosphorylation. NHF1 cells transfected with
cdc6 siRNA displayed a decrease in cyclin D protein levels (Fig. 2B), consistent with what we
and others have recently observed in both Mcm7-depleted and Cdc6-depleted cells.21 In
contrast, cyclin E levels remained constant in Cdc6-depleted cells (Fig. 2C).
Given the overall poor Rb phosphorylation, we reasoned that—in addition to Cdk4 activity—
Cdk2 activity must also be low in Cdc6-depleted cells even though cyclin E levels were not.
To test that notion directly, we compared the histone H1 kinase activity in both cyclin E and
Cdk2 immunoprecipitates from lysates of control and Cdc6-depleted cells. Cdc6 depletion
caused substantial reductions in both in cyclin E-associated kinase activity (Fig. 2C, compare
lanes 2 and 3) and Cdk2 activity (Fig. 2D, compare lanes 4 and 5). To determine if the effect
of Cdc6 depletion on cyclin E-associated kinase activity occurred during G1, we synchronized
siRNA transfected cells by serum withdrawal shortly after siRNA transfection and before any
detectable loss of Cdc6 protein had occurred (data not shown). We serum-stimulated the
quiescent cells and analyzed whole cell lysates for cyclin E protein and cyclin E
immunoprecipitates for histone H1 kinase activity. Cdc6 protein was undetectable in serum-
starved cells (t = 0 h), but serum stimulation induced Cdc6 protein in control cells by 10 h (Fig.
2E, lane 6) at a timepoint close to the G1/S transition (data not shown, but see also Fig. 4C).
Importantly, cyclin E-associated kinase activity was lower in the Cdc6-depleted cells compared
to control cells during G1 (Fig. 2E, 6 h).
We could not attribute the reduced cyclin E/Cdk2 activity to differences in the levels of cyclin
E protein either in the whole cell lysates or in the immunoprecipitates (Fig. 2E, immunoblots).
Cdk2 activity is blocked by association with inhibitors such as p21 and p27,22 but Cdc6
depletion had little effect on the overall abundance of either p21 or p27 in either whole cell
extracts (Fig. 3A, first and second rows) or in Cdk2 immunoprecipitates (Fig. 3A, compare
lanes 4 and 5). A previous report of the effects of origin licensing inhibition by depletion of
the Orc2 protein suggested that licensing inhibition leads to an increase in p21 levels.10 We
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found however, that Orc2 depletion in NHF1 cells did not have this effect despite the fact that
Orc2 was depleted enough to induce a reduction in BrdU incorporation (Fig. 3B). These results
indicated that at least one mechanism other than changes in cyclin abundance or CDK inhibitor
binding links origin licensing to Cdk2 activity.
DNA damage and replication stress can trigger a well-characterized checkpoint response that
blocks the G1/S transition. Important activities in this pathway include the p53 tumor
suppressor, and the Chk1 and Chk2 protein kinases (reviewed in refs. 23–28). We probed cell
extracts with antibodies to the phosphorylated and activated forms of p53, Chk1 and Chk2. As
a positive control for detecting the phosphorylation of p53, Chk1 and Chk2, we treated NHF1
cells with hydroxyurea (HU) for 24 h. Although phosphorylation of Chk1, Chk2 and p53 were
readily detectable in HU-treated cells, indicating that our antibodies were sufficiently sensitive
to detect these markers (Fig. 3C, lane 1), we observed no induction of these modifications in
Cdc6-depleted cells (Fig. 3C, compare lanes 2 and 3). We further evaluated cells from 24 h to
72 h after transfection with cdc6 siRNA to determine if a transient increase in DNA damage
checkpoint signaling could be detected, but we found no evidence that the damage checkpoint
was ever activated after cdc6 siRNA treatment (data not shown). Particularly during a DNA
damage response, Cdk2 can also be regulated by Wee1-mediated inhibitory phosphorylation
at amino acids T14 and Y15, and retention of phosphorylation at these sites blocks S phase
entry.29–31 Using immunoblot analysis, we detected no increase in the level of this inhibitory
phosphorylation in Cdc6-depleted cells compared to control cells (Fig. 3C, compare lanes 4
and 5), nor did we detect changes in abundance of the Cdc25A phosphatase responsible for
removing the inhibitory phosphorylations on Cdk2 (data not shown). Therefore, the reduced
cyclin E-kinase activity was not due to retention of the inhibitory tyrosine phosphorylation of
Cdk2.
Cdk2 activity requires phosphorylation at threonine 160 in the “activation loop.”32,33 Using
an antibody that specifically recognizes T160 phosphorylation, we discovered that this
activating modification of Cdk2 was reduced in Cdc6-depleted cells compared to control cells
(Fig. 3D, first row), while total Cdk2 levels remained the same (Fig. 3D, second row). To test
if these molecular phenotypes associated with Cdc6 depletion are detectable in other normal
human cells, we transfected diploid human lung fibroblasts (WI-38 cells) with cdc6 siRNA,
then analyzed BrdU incorporation, Cdk2 T160 and Rb phosphorylation. As in NHF1 cells,
Cdc6 depletion resulted in a ~6-fold reduction in S phase cells (Fig. 3E, bar graph) and
importantly, loss of both Cdk2 and Rb phosphorylation (Fig. 3E, first and second rows). We
obtained similar results in another telomerase-expressing fibroblast line, NHF10 and with
multiple cdc6 siRNA sequences (data not shown).
The G1 arrest and Cdk2 phosphorylation defect could be specific consequence of the loss of
Cdc6 protein, or it could be a general consequence of the licensing defect caused by loss of
Cdc6 function. To distinguish between these possibilities, we depleted NHF1 cells of Cdt1
which, like Cdc6 depletion, caused the predicted MCM chromatin loading defect (data not
shown). Also, like Cdc6 depletion, Cdt1 depletion caused a reduction in the number of S phase
cells (Fig. 3F, bar graph) with no obvious signs of cell death (data not shown). Moreover, Cdt1
depletion induced a loss of both Cdk2 and Rb phosphorylation (Fig. 3F, first and second rows,
respectively) and a reduction in Cdk2 activity in vitro (data not shown). These results further
confirm that the effects of the siRNAs are attributable to the origin licensing defect rather than
an off-target effect of the siRNAs, since the cdc6 and cdt1 siRNAs target different components
of the prereplication complex.
Cdk2 activation and nuclear accumulation during G1 are delayed in Cdc6-depleted cells
In human cells, the activating phosphorylation of all CDKs is primarily attributed to CDK
activating kinase (CAK), a heterotrimeric complex of Cdk7, cyclin H and Mat1.34 A logical
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explanation for the reduction of Cdk2 T160 phosphorylation would be the loss of CAK activity,
but the total amount of Cdk7, cyclin H and Mat1 were not reduced in Cdc6-depleted cells
compared to control-treated cells (Fig. 4A). We also examined the catalytic activity of CAK
in control and Cdc6-depleted cells by immunecomplex kinase assays of cyclin H
immunoprecipitates using the C-terminal domain of RNA polymerase II (a standard substrate
for this kinase35). Cdc6-depleted G1 cells showed no reduction in CAK activity in vitro
compared to control cells using either RNA PolII (Fig. 4B) or Cdk2 as a substrate (data not
shown). These observations demonstrate that neither downregulation of CAK subunit
expression nor reduced CAK enzymatic activity account for reduced Cdk2 T160
phosphorylation.
We considered the possibility that a defect in Cdk2 phosphorylation by CAK could instead be
explained by enzyme-substrate accessibility. Previous studies have noted that changes in Cdk2
T160 phosphorylation are often accompanied by changes in Cdk2 localization. In quiescent
fibroblasts, Cdk2 resides primarily in the cytoplasm, but late in G1 it accumulates in the nucleus
by a mechanism that is still incompletely understood.36–40 Since all subunits of CAK are
constitutively expressed in the nucleus,41 the decrease in Cdk2 phosphorylation on T160 in
quiescent cells could be explained (at least in part) to the absence of Cdk2 in the nucleus. To
investigate if the defect in Cdk2 phosphorylation in Cdc6-depleted cells included altered Cdk2
nuclear accumulation, we again prepared Cdc6-depleted synchronized NHF1 cells (as in Fig.
2E) and examined not only the chromatin fractions for Cdc6 and MCM association, but also
the nuclear and cytoplasmic fractions for total Cdk2 and Cdk2 phosphorylated on T160. As
expected, NHF1 cells transfected with cdc6 siRNA delayed S phase entry (Fig. 4C and D). By
10 h, the rise in Cdc6 protein levels was accompanied by an increase in Mcm2 chromatin
association in the control cells. As expected, cells depleted of Cdc6 were deficient in Mcm2
chromatin loading during G1 (Fig. 4E). It should be noted that despite the fact that these siRNA
transfections are highly effective in suppressing Cdc6 protein expression and MCM loading,
they are not likely to phenocopy a true null; the small number of cells entering S phase in the
Cdc6-depleted population presumably reflects the activity of the residual Cdc6 protein in a
small fraction of cells.
Consistent with previous observations,36,39,40 total Cdk2 protein was predominantly
cytoplasmic in G0 cells, but the levels of nuclear Cdk2 protein increased in late G1 in control
transfected cells (Fig. 4F, top row, compare lanes 1 and 5). On the other hand, Cdk2 nuclear
accumulation was delayed in Cdc6-depleted cells, particularly noticeable at the time of the
G1/S transition in control cells (Fig. 4F, 10 h, lane 6). These localization effects were
accompanied by poor phosphorylation of Cdk2 on T160 (Fig. 4F). The observed delay in Cdk2
nuclear accumulation in Cdc6-depleted cells, coupled with a constitutively nuclear CAK,
represents at least one mechanism to explain the defect in Cdk2 T160 phosphorylation in Cdc6-
depleted cells.
The cell cycle arrest in Cdc6-depleted NHF1 cells requires p53
The differential response of normal and cancer cells to licensing inhibition (Fig. 1 and refs.
11 and 12) suggested that a commonly mutated pathway in cancer cells is involved in
coordinating licensing with G1 progression. The p53 tumor suppressor pathway is deregulated
in the vast majority of human cancers, so we considered p53 a candidate for participation in
the G1 arrest induced by Cdc6 depletion. To test this idea, we performed co-depletion
experiments using p53 siRNA. As before, transfection with cdc6 siRNA alone reduced the
number of S phase cells from 16.7% in control cells to 5.7% in Cdc6-depleted cells (Fig. 5A,
compare control and si-cdc6). Depletion of p53 alone had little effect on the cell cycle profile
of normal cells under these conditions (Fig. 5A, compare control and si-p53). Co-depletion of
p53 24 h after transfection with cdc6 siRNA completely prevented the cell cycle effects of
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Cdc6 depletion, fully restoring the number of S phase cells to control numbers (Fig. 5A,
compare si-cdc6 and si-cdc6/p53). Conspicuously, the low intensity of the BrdU staining in
the co-depleted cells (note the y-axis) suggested that even though the co-depleted cells entered
S phase, replication was still very inefficient. Depletion of p53 did not rescue Cdc6 expression
(Fig. 5B), which likely accounts for the reduced DNA synthesis rate. Virtually identical results
were obtained when p53 was co-depleted with Cdt1 (Fig. 5C and D), indicating that p53 is
required for the cell cycle effects of the licensing defect (i.e., loss of Cdc6 and Cdt1 functions)
rather than the loss of Cdc6 or Cdt1 proteins.
We further tested for dependence on p53 for the delayed S phase entry in synchronized cells
following the same procedure as in Figure 4. Cdc6 expression was undetectable in quiescent
cells but induced in control cells by serum stimulation, and p53 depletion did not change either
of these findings (Fig. 5E). As expected, Cdc6-depleted NHF1 cells delayed S phase entry
compared to control cells (Fig. 5F, gray and black bars). NHF1 cells depleted of p53 alone
slightly delayed S phase entry when compared to control cells (Fig. 5F, white bars), but more
importantly, cells co-depleted of Cdc6 and p53 entered S phase in numbers similar to both the
control and p53-depleted cells (Fig. 5F, checkered bars). Cdc6 and Cdt1 are essential
replication factors, so we attribute the DNA replication in cells co-depleted of p53 and Cdc6
or p53 and Cdt1 to the very low levels of origin licensing supported by the scant Cdc6 or Cdt1
protein in these experiments. Importantly, the rescue of the S phase population implies that in
the cells transfected with just cdc6 or cdt1 siRNA there were indeed a small number of licensed
origins present, but they did not fire due to p53-dependent restraint.
Cells that fail to arrest in response to origin licensing inhibition fail to downregulate Rb and
Cdk2 phosphorylation
The observation that Cdc6 depletion resulted in reduced phosphorylation of both Rb and Cdk2
T160 prompted us to test if the suppression of the cell cycle defect by co-depletion of p53 also
suppressed these molecular phenotypes. We probed lysates of cells transfected with siRNAs
targeting Cdc6 and p53, either singly or in combination, for phosphorylation of Rb and Cdk2
on T160 as in Figures 2 and 3. As we had observed before, Cdc6-depleted cells were
characterized by poor Rb and Cdk2 phosphorylation (Fig. 6A, compare lanes 1 and 2). Co-
depletion of p53 with Cdc6 largely restored both Rb phosphorylation and Cdk2
phosphorylation (Fig. 6A, compare lanes 2 and 3 with lane 1), in keeping with the near-
complete rescue of the S phase population (Fig. 5A, D and F). Previous reports that origin
licensing inhibition induces apoptosis in a wide variety of transformed cell lines11,12 (including
HeLa and U2OS, Fig. 1), suggested that these cells might be unable to induce the same G1
arrest that normal cells do. To determine if cancer cell lines were specifically defective in
downregulating both Rb phosphorylation and Cdk2 T160 phosphorylation, we probed for these
markers in Cdc6-depleted HeLa and U2OS cells. Despite effective Cdc6 depletion, neither
HeLa nor U2OS cells showed the same loss of Rb and Cdk2 phosphorylation that we observed
in the normal cells (Fig. 6B, compare lane 1 with 2 and lane 3 with 4). Thus, not only are HeLa
and U2OS cells sensitive to apoptosis by Cdc6 depletion, but they are incapable of regulating
the markers of a G1 arrest that the Cdc6-depleted NHF1 cells did.
If these cancer cell lines failed to arrest in G1, then an attempted S phase with low levels of
origin licensing would be predicted to result in sparsely distributed replication forks. The
partially replicated chromosomes would be more susceptible to fork collapse and double-strand
breaks. To test this prediction, we probed the Cdc6-depleted cancer cells for a marker of DNA
double-strand breaks, ATM-dependent phosphorylation of Chk2 on T68. In both cell lines,
Chk2 phosphorylation was induced by Cdc6 depletion (Fig. 6B, third row). These observations
suggest that HeLa and U2OS cells could not arrest in G1 as a consequence of an origin licensing
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defect, but since they could not complete S phase either, the partially replicated chromosomes
accumulated DNA damage.
If this description accurately reflects what happened in the cancer cell lines, then we predicted
that the Cdc6-depleted normal cells that inappropriately entered S phase due to co-depletion
of p53 should also contain phosphorylated Chk2. We therefore probed lysates of the co-
depleted NHF1 cells for phospho-Chk2. As before (Fig. 3C), depletion of Cdc6 alone did not
induce any detectable markers of a DNA damage response (Fig. 6C, compare lanes 1 and 2),
and neither did depletion of p53 (Fig. 6C, lane 3). In contrast to these single depletions, co-
depletion of p53 with Cdc6 led not only to S phase entry (Fig. 5), but also to accumulation of
phospho-Chk2 (Fig. 6C, lane 4). In a sense, depletion of p53 from the normal fibroblasts
allowed them to phenocopy the cancer cells.
Discussion
In this study we demonstrate that the activity of cyclin E/Cdk2 in late G1 depends on the
licensing of replication origins. Similar Cdk2 downregulation and Rb hypophosphorylation
was observed in both Cdc6-depleted cells (that express Cdt1) and in Cdt1-depleted cells (that
express Cdc6). The disruption common to both Cdc6 and Cdt1 depletion is the failure to fully
load MCM complexes at origins, indicating that it is origin licensing itself that is required for
Cdk2 activation and Rb phosphorylation. We conclude that the low activity of Cdk2 in Cdc6-
depleted or Cdt1-depleted fibroblasts was primarily due to failure to phosphorylate Cdk2 on
T160 since no other major CDK regulatory mechanism was perturbed in these cells. The
physiological circumstances leading to inhibition of CDK activation by phosphorylation are
not as well studied as most other forms of CDK regulation, so the finding that this event is
responsive to licensing inhibition represents a novel aspect of CDK control. In further support
of a link between licensing and CDK activation, Kan et al. observed a correlation between
Cdc6 expression and Cdk2 phosphorylation during recovery from MMS-induced checkpoint
arrest.42
We observed that expression of CAK subunits was not inhibited in licensing-deficient cells
(Fig. 4A) suggesting that the downregulation of Cdk2 phosphorylation is due to other
perturbations such as nuclear accumulation of Cdk2 (Fig. 4F). It should be noted however that
even though there was a reduction in the nuclear pools of Cdk2 in Cdc6-depleted cells, this
effect may not be the only reason Cdk2 was not phosphorylated in licensing-deficient cells.
Lentz et al. noted that even a constitutively nuclear Cdk2 fusion still required one or more
serum-stimulated events in late G1 for Cdk2 phosphorylation on T160.43 The results presented
here suggest that origin licensing could be that event.
We also demonstrate that p53 is required for licensing-deficient cells to downregulate Cdk2
T160 and Rb phosphorylation, and p53-depleted normal cells fail to delay S phase entry when
licensing is inhibited. An important conclusion from this finding is that Cdc6-depleted or Cdt1-
depleted cells had a low level of origin licensing (note for instance the faint Mcm2 band in
lane 4 of Fig. 1E), but these few licensed origins did not fire on schedule as long as p53 was
expressed at normal levels. In other words, the normal cells treated with only cdc6 siRNA
licensed enough origins for a very weak or inefficient S phase, but the presence of normal
amounts of p53 prevented them from crossing the restriction point, entering S phase, and firing
those few origins. During G1, MCM loading closely coincided with Cdk2 phosphorylation on
T160 (Fig. 4E and F). It may be that a critical threshold of MCM loading must be reached in
G1 before efficient Cdk2 activation can take place. This coordination of Cdk2 activation with
licensing is suggestive of a cell cycle checkpoint relationship that serves to ensure that S phase
does not begin before a critical task in G1, origin licensing, has been accomplished.
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We note that a majority of cancer cells have disruptions in the regulation of both p53 and Rb;
in the case of HeLa cells these disruptions include expression of the HPV E6 and E7 proteins,
and in U2OS cells it is overexpression of the p53 ubiquitin ligase, MDM2,44 and loss of the
p16 Cdk4 inhibitor.45 These cancer cell lines behave similarly to the p53-depleted NHF1 cells
when licensing is blocked by depletion of Cdc6 in that they fail to downregulate Cdk2 and Rb
phosphorylation. Many cell cycle studies have explored CDK regulation only in cancer cell
lines (e.g., HeLa cells) where the dependence of Cdk2 phosphorylation on origin licensing
during G1 could not have been observed.
Despite the fact that p53 is required for the cell cycle response to licensing inhibition, Cdc6-
depleted cells do not activate the canonical DNA damage checkpoints since neither upstream
markers (phosphorylation of Chk1 and Chk2) nor downstream targets (p53, p21 or Cdk1 and
Cdk2 Y15 phosphorylation) are induced by Cdc6 depletion. One possible role for p53 in
making normal cells sensitive to an origin licensing checkpoint is maintaining basal expression
of a cohort of growth inhibitory genes. For example, in p53-deficient NHF1 cells, basal levels
of p21 are low and Cdk2 activity is correspondingly higher (our unpublished observations).
Although our results indicate that origin licensing is required to promote Cdk2
phosphorylation, we call attention to the fact that these are not the only important events in
G1 that respond to the status of origin licensing. Rb phosphorylation can be carried out not
only by Cdk2, but also by cyclin D/Cdk4, and indeed it has been reported that Cdk4 and Cdk6
are principally responsible for the phosphorylation of S807 and S811 that we monitored in this
study.19 If cyclin D-dependent kinase activity were unaffected by origin licensing then we
would have expected Rb phosphorylation to remain high in Cdc6-depleted cells. Our
demonstration that cyclin D protein levels are low (Fig. 2B) combined with our indirect
measurement of Cdk4/6 activity (Rb phosphorylation in vivo) indicates that Cdk4/6 activity
must also be low, and this conclusion is strongly supported by the more extensive analysis of
Cdk4 activity in Liu et al.21 In that study, origin licensing inhibition by Mcm7 depletion in
synchronized normal cells during G1 resulted in reduced Cdk4 activity due to low transcription
of the cyclin D gene. Thus, we conclude that origin licensing is required for full activity of
both early G1 CDK activity (cyclin D/Cdk4) and late G1 CDK activity (cyclin E/Cdk2).
The consequences of poor origin licensing may be even more global than just regulation of
CDK activity however. The molecular markers we have examined in this study and in the study
by Liu et al. are indicative of a cellular state that is more similar to quiescence than to G1,
despite the fact that growth factor stimulated signal transduction pathways appear unaffected
(our unpublished observations and ref. 21). A “pseudo-quiescent” state induced by failure to
license origins may explain why bypass of the G1 arrest has thus far only been achieved by
manipulations that cause pleiotropic effects such as expression of HPV E621 or depletion of
p53.
Given that mammalian MCM proteins are constitutively nuclear,46–49 the events in G1 that are
reduced in licensing-deficient cells must be sensitive to a difference between chromatin-bound
MCM complex and the absence of chromatin-bound MCM (model in Fig. 6D). An emphasis
on chromatin localization further supported by a recent proteomics analysis by Khoudoli et al.
50 These investigators examined the entire collection of proteins that associate with X. laevis
chromatin under normal licensing conditions in vitro and when licensing is blocked by excess
geminin which inhibits Cdt1 function.14,51,52 Intriguingly, proteins affected in the geminin-
treated samples included not only the predicted MCM subunits, but also factors involved in a
surprising variety of nuclear processes including nuclear pore assembly, nuclear structure,
chromatin remodeling, and DNA repair. If these results are applicable to human cells, then
origin licensing could be a step that is critical not only for DNA replication, but also for many
aspects of cell cycle progression.
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Cell culture and siRNA transfection
Normal human fibroblasts immortalized with human telomerase (NHF1-hTert) and cancer cell
lines (HeLa and U2OS) were cultured in Dulbecco’s modified Eagle’s medium (Gibco,
Invitrogen) containing 10% fetal bovine serum (Sigma) and 2 mM L-glutamine (Sigma). WI-38
lung fibroblasts were cultured in Minimum Eagles medium (Gibco) containing 10% fetal
bovine serum (Sigma), 1X nonessential amino acids (Gibco) and 2 mM L-glutamine (Sigma).
All cultures were maintained in a humidified incubator at 37°C and 5% CO2.
Log phase normal fibroblasts were plated at a density of 1.35 × 105 per 100-mm dish 24 h prior
to transfection. SiRNA oligonucleotides were synthesized by Invitrogen (GFP control, 5'-GGC
UAC GUC CAG GAG CGC ACC TT-3'; cdc6 siRNA- 2144, 5'-UCU AGC CAA UGU GCU
UGC AAG UGU A-3'; cdc6 siRNA-2534, 5'-CAC CAU GCU CAG CCA UUA AGG UAU
U-3'; p53 siRNA, 5'-AAG GAA GAC UCC AGU GGU AAU-3'; cdt1 siRNA, 5'-CCU ACG
UCA AGC UGG ACA ATT-3'). Transfections were performed with a total of 75 nM siRNA
duplex using Dharmafect 1 reagent (Dharmacon) according to the manufacturer’s guidelines.
Equal amounts of both cdc6 siRNA molecules were used (37.5 nM each). The following day,
the total volumes were brought to 10 ml with fresh medium, and cultures were typically
incubated for an additional 48 h. In the case of co-depletion of p53 and Cdc6 or Cdt1, cells
were transfected with p53 siRNA 24 h after cdc6 or cdt1 siRNA, and examined 72 h after the
initial transfection. For Orc2 depletions, log phase normal fibroblasts were seeded at 80%
confluence in 6-cm dishes and transfected with 100 nM Orc2 or control siRNA the following
day. Cells were incubated for 24 h, then split into 10-cm dishes, and transfected again 24 h
later. Cells were collected 72 h after the second siRNA transfection.
Cell synchronization
Asynchronously growing fibroblasts were plated at a density of 2.5 × 105 cells per 100-mm
dish and transfected 24 h later, as described above, except that 100 nM siRNA was used. Twelve
hours later, the transfection solution was removed and replaced with medium containing 0.1%
FBS. After 72 h in low serum, cells were stimulated by the addition of 10% FBS and collected
at the indicated times after stimulation.
Immunoblot analysis
Total cell lysates were prepared by resuspending pellets in lysis buffer containing 0.1% Triton
X-100, 0.1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 1 mM
orthovanadate, 1 mM β-glycerolphosphate, 5 µg/ml phosvitin, 1 µg/ml leupeptin, 1 µg/ml
aprotinin and 1 µg/ml pepstatin A (all from Sigma) in phosphate-buffered saline (PBS); protein
concentrations were determined by the Bradford assay (Bio-Rad). Chromatin fractions were
prepared as previously described.13 Samples containing equal amounts of protein were
combined with Laemmli sample buffer [10% glycerol, 0.05 M Tris (pH 6.8), 0.1%
bromophenol blue, 1% SDS] containing 10% beta-mercaptoethanol and boiled. Samples were
separated by SDS-PAGE and transferred to PVDF membrane (Millipore) and probed with
appropriate antibodies to detect the following proteins: Cdc6 (sc-9964), p53 (sc-126), cyclin
H (sc-609), cyclin D1 (sc-295), Mat1 (sc-13142) and cdk2 (M2, sc-163) from Santa Cruz
Biotechnology; HSP90 (4874), phospho-Chk1 (S345), phospho-Chk2 (Th68), phospho-Rb
(S807/811), phospho-Cdc2/Cdk2 (Y15), phospho-Cdk2 (T160) and phospho-p53 (S15) from
Cell Signaling Technologies; Mcm2 (BM-28), Orc2, Cdc25A and Rb from BD Pharmingen;
fibrillarin from Abcam; tubulin (DM1A) from Sigma; and p21 (Ab-10), Cdk7 (MO-1.1), cdk2
(2B6), p27 (DCS-72.F6) and cyclin E (HE12) from Neomarkers. Antibodies detecting p27 and
cyclin E were gifts from Dr. Yue Xiong (University of North Carolina at Chapel Hill). Anti-
Cdt1 antiserum was described previously.14 We confirmed the specificity of the phospho-
Nevis et al. Page 9













Cdk2 (T160) antibody using myc epitope-tagged normal and T160A mutant forms of Cdk2
(gift of J. Baldassare) expressed in transfected 293 cells (data not shown).
For nuclear fractionation, cells were incubated on ice for 30 min in hypotonic lysis buffer
containing 10 mM HEPES-KOH pH 7.5, 10 mM KCl, 3 mM MgCl2, 1 mM EDTA, 0.05%
NP-40, 1 mM DTT, 0.1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
(AEBSF), 0.5 mM orthovanadate, 1 mM β-glycerol phosphate, 10 µg/ml phosvitin, 1 µg/ml
leupeptin, 1 µg/ml aprotinin and 1 µg/ml pepstatin A. Extracts were centrifuged at 600 ×g for
5 min and cytosolic fractions (supernatant) were transferred to new tubes. Nuclei were washed
with hypotonic buffer and resuspended in Laemmli sample buffer. Cytosolic fractions were
quantified by Bradford assay, and equivalent amounts of protein (typically 30 µg) were
separated by SDS-PAGE. Nuclear extracts corresponding to twice the cell equivalents of the
paired cytosolic extracts were loaded. Fibrillarin (nuclear) and HSP90 (cytoplasmic) were used
as fractionation controls.
Cell cycle and cleaved caspase-3 analysis
Cells to be analyzed by flow cytometry were labeled with 10 µM BrdU for 1 h prior to
trypsinization and ethanol fixation. Nuclei were stained with fluorescein isothiocyanate
(FITC)-labeled anti-BrdU antibody (BD Biosciences) and counterstained with propidium
iodide. Nuclei were analyzed using the CyAn (DakoCytomation), and cell cycle distributions
were determined using Summit v4.3 software (DakoCytomation). The fraction of apoptotic
cells was determined using an active caspase-3 antibody kit (BD Pharmingen), according to
the manufacturer’s guidelines.
Kinase assays
Cells were lysed for 30 min at 4°C in RIPA (50 mM Tris-HCL, pH 8.0, 200 mM NaCl, 0.5%
NP-40, 1 mM dithiothreitol, 50 µg/ml of AEBSF, 10 µg/ml aprotinin, 20 mM NaF, 0.1 mM
sodium orthovanadate). Lysates were clarified and subjected to immunoprecipitation with
either anti-cyclin E antiserum, anti-Cdk2 (M2) or anti-cyclin H and protein A-agarose for a
total of 3 h. Beads were washed twice with buffer A (20 mM Tris-HCL, pH 8.0, 250 mM NaCl,
1 mM EDTA, 0.5% NP-40), twice in buffer B (buffer A but containing 100 mM NaCl), and
then once in kinase buffer (50 mM Tris-HCL, pH 7.5, 10 mM MgCl2 and 1 mM DTT). Kinase
reactions were carried out in 25 µl kinase buffer containing 5 µg of histone H1 (Sigma) or the
C-terminal domain of RNA Pol II (purified as a GST fusion from E. coli), 1 µM ATP, and 5
µCi [γ-32P]ATP (Perkin Elmer) and incubated at 30°C for 30 min. Reactions were stopped
with 1X SDS sample buffer, boiled and separated on 10% SDS-PAGE. Gels were washed 3
times by soaking them for 15 min each in buffer C (20 mM Tris base, 200 mM glycine, 0.1%
SDS, 10% glycerol, 1% sodium pyrophosphate), dried and autoradiographed. Relative
phosphorylation of histone H1 or CTD was determined using the ImageJ program (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/, 1997–2006).
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Cdc6 depletion induces apoptosis in HeLa and U2OS cells but not normal human fibroblasts.
(A) HeLa, U2OS or NHF1-hTert (NHF1) cells were transfected with a total of 75 nM of control
siRNA (targeting GFP) or cdc6 siRNA and incubated for 72 h. Whole cell lysates were
subjected to immunoblot analysis for endogenous Cdc6 and tubulin. (B) Portions of the samples
in A were analyzed by flow cytometry after staining with propidium iodide for DNA content
(x-axis). The percentage of sub-G1 cells is gated and shown on the histograms. The percentage
of S phase cells for each population is listed below the corresponding histograms. (C) NHF1,
HeLa and U20S cells transfected with the indicated siRNAs for 96 h were evaluated for
caspase-3 cleavage by flow cytometry. The bar graph represents the average of three
independent experiments. (D) NHF1 cells were transfected with control or cdc6 siRNA for 72
h, labeled for 1 h with BrdU, and analyzed by flow cytometry with anti-BrdU antibody to detect
DNA synthesis (y-axis) and with propidium iodide for DNA content (x-axis). (E) Whole cell
extracts and chromatin-bound fractions from the cells in (D) were evaluated for MCM, Cdc6,
Orc2 and tubulin by immunoblotting.
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Cdc6 depletion prevents cyclin E/Cdk2 activation during G1. (A) Whole cell extracts from
NHF1 cells transfected with control or cdc6 siRNA as in Figure 1D were probed with antibodies
to total Rb or with a phosphospecific antibody that recognizes Rb phosphorylated at S807 and
S811 and for total Cdc6 and tubulin. (B) Whole cell extracts from siRNA-transfected NHF1
were probed with antibodies to cyclin D1, Cdc6 and tubulin. (C) Extracts of siRNA-transfected
NHF1 cells were subjected to immunoprecipitation with normal rabbit serum (“NS” lane 1) or
with anti-cyclin E antibody (lanes 2 and 3). The precipitates were divided and analyzed by
immunecomplex kinase assay with purified histone H1 and [γ-32P]ATP, followed by SDS-
PAGE (top row) or analyzed for cyclin E protein by immunoblotting (bottom row). The bar
graph reports average cyclin E-associated H1-kinase activity in cells depleted of Cdc6 relative
to the corresponding control cells in three independent experiments. (D) Extracts of siRNA-
transfected NHF1 cells were treated as in (C), except that the immunoprecipitations and
immunoblot utilized anti-Cdk2 antibody. The bar graph reports average Cdk2 H1-kinase
activity in cells depleted of Cdc6 relative to the corresponding control cells in three independent
experiments. (E) NHF1 cells were transfected with a total of 100 nM of control or cdc6 siRNA
for 12 h, then incubated for 72 h in medium containing low serum (0.1% FBS). Cells were
released from growth arrest by addition of 10% FBS, labeled for 1 h with BrdU immediately
prior to each collection point at 0, 6 and 10 hours after serum addition. Immunecomplex kinases
assays were performed as in (C).
Nevis et al. Page 15














Licensing inhibition prevents Cdk2 phosphorylation at T160. (A) Whole cell lysates and anti-
Cdk2 immunoprecipitates were probed for the CDK inhibitors, p21 and p27 by
immunoblotting. (B) NHF1 cells were transfected with orc2 siRNA for a total of 120 hrs. BrdU
incorporation was analyzed as in Figure 1D resulting in average (of two experiments) 29% S
phase for control treated and 4.9% for orc2 siRNA treated cells. Whole cell lysates were probed
for endogenous p21, Orc2 and tubulin by immunoblotting. (C) NHF1 cells were transfected
with control or cdc6 siRNA for 72 h (lanes 2 and 3) or treated with 2 mM hydroxyurea for 24
h (lane 1). Whole cell extracts were immunoblotted with antibodies to detect p53
phosphorylated at S15, Chk2 phosphorylated at T68, Chk1 phosphorylated at S317, Cdk1 and
Cdk2 phosphorylated at Y15 (the antibody recognizes both kinases), Cdc6 and tubulin as
indicated. (D) Extracts were transfected as in (C) except, that whole cell extracts were probed
for phospho-Cdk2 (T160), Cdc6 and tubulin. (E) WI-38 cells (diploid lung fibroblasts) were
transfected with a total of 75 nM of control or cdc6 siRNA, incubated for 72 h and processed
for flow cytometric analysis as in Figure 1D. The bar graph reports the average percentage S
phase cells in three independent experiments (left). The remaining samples were subjected to
immunoblot analysis, and a representative set of blots is shown (right). (F) NHF1 cells were
transfected with a total of 75 nM of control or cdt1 siRNA and analyzed as in (E).
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Cdc6 depletion prevents Cdk2 nuclear accumulation in G1. (A) Whole cell extracts of
asynchronous NHF1 cells transfected with control or cdc6 siRNA for 72 h were probed for
endogenous cyclin H, Cdk7, Mat1 and Cdc6; a non-specific band serves as a loading control.
(B) NHF1 extracts were transfected as in Figure 2E and subjected to immunoprecipitation with
normal rabbit serum or with anti-cyclin H antibody. The precipitates were divided and analyzed
by immunecomplex kinase assay with purified histone CTD and [γ-32P] ATP, followed by
SDS-PAGE (top row) or analyzed for cyclin H protein by immunoblotting (bottom row). A
portion of the extracts were probed for endogenous cyclin H and Cdc6. A non-specific band
served as a loading control for the whole cell extracts. (C) NHF1 cells were transfected with
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siRNA and synchronized by serum deprivation as in Figure 2E. BrdU incorporation was
evaluated by flow cytometry; histograms from a representative experiment are shown. (D) Bar
graph documenting the number of BrdU positive cells from three independent experiments as
in (C). (E) Cells were treated as in (B), and Mcm2 and Cdc6 were detected in chromatin-bound
fractions and in whole cell lysates; a non-specific band serves as a loading control. (F) Portions
of the cells in (B) were fractionated by hypotonic lysis into cytosolic and nuclear fractions
which were probed by immunoblotting for total Cdk2, phospho-Cdk2 (T160), Cdc6, fibrillarin
(nuclear protein control) and HSP90 (cytosolic protein control).
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p53 is required for licensing-deficient cells to delay S phase entry. (A) NHF1 cells were
transfected with a total of 75 nM of control or cdc6 siRNA, 24 h later cells were transfected
with control (GFP) or p53 siRNA and incubated an additional 48 h. Cell cycle profiles were
generated as in Figure 1D. (B) Immunoblots of extracts of the cells analyzed in (A) by flow
cytometry with the indicated antibodies. (C) NHF1 cells were transfected with control, cdt1,
p53 or cdt1 and p53 siRNA for 72 h. Immunoblots of whole cell extracts were probed to detect
p53, Cdt1 and tubulin. (D) Average BrdU incorporation from three independent transfections
of the experiment shown in (C). (E) NHF1 cells were transfected as in Figure 4B. Cells were
released from growth arrest by addition of 10% FBS, labeled for 1 h with BrdU prior to each
collection point at 0 and 14 h after serum addition. Immunoblots of whole cell lysates were
probed for the indicated proteins. (F) Average BrdU incorporation from three independent
transfections of the experiment shown in (B).
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p53 is required for downregulation of Cdk2 and Rb phosphorylation in licensing-deficient cells.
(A) Whole cell extracts from control, cdc6, p53 or Cdc6 and p53 siRNA transfected NHF1
cells were probed with antibodies to detect phospho-Rb (S807/S811), phospho-Cdk2 (T160),
p53, Cdc6 and tubulin. (B) HeLa and U20S cells were transfected with control or cdc6 siRNA,
and whole cell extracts were subjected to immunoblot analysis with antibodies to detect
phospho-Cdk2 (T160), phospho-Rb (S807/ S811), phospho-Chk2 (T68), Cdc6 and tubulin.
(C) Whole cell extracts from control, cdc6, p53 or Cdc6 and p53 siRNA transfected NHF1
cells were probed for phospho-Chk2, p53, Cdc6 and tubulin. (D) Model summarizing the
results described in this study.
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